Nautilus Biotechnology Stock Short Ratio
| NAUT Stock | USD 2.58 0.11 4.09% |
Nautilus Biotechnology fundamentals help investors to digest information that contributes to Nautilus Biotechnology's financial success or failures. It also enables traders to predict the movement of Nautilus Stock. The fundamental analysis module provides a way to measure Nautilus Biotechnology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Nautilus Biotechnology stock.
Nautilus | Short Ratio |
Nautilus Biotechnology Company Short Ratio Analysis
Nautilus Biotechnology's Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
Current Nautilus Biotechnology Short Ratio | 16.65 X |
Most of Nautilus Biotechnology's fundamental indicators, such as Short Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Nautilus Biotechnology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Nautilus Short Ratio Driver Correlations
Understanding the fundamental principles of building solid financial models for Nautilus Biotechnology is extremely important. It helps to project a fair market value of Nautilus Stock properly, considering its historical fundamentals such as Short Ratio. Since Nautilus Biotechnology's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Nautilus Biotechnology's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Nautilus Biotechnology's interrelated accounts and indicators.
Click cells to compare fundamentals
The higher the Short Ratio, the longer it would take to buy back the borrowed shares. In theory, the more short positions are currently outstanding, the faster it will be to cover shorted positions.
| Competition |
Based on the latest financial disclosure, Nautilus Biotechnology has a Short Ratio of 16.65 times. This is 326.92% higher than that of the Biotechnology sector and 124.7% higher than that of the Health Care industry. The short ratio for all United States stocks is notably lower than that of the firm.
Nautilus Short Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Nautilus Biotechnology's direct or indirect competition against its Short Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Nautilus Biotechnology could also be used in its relative valuation, which is a method of valuing Nautilus Biotechnology by comparing valuation metrics of similar companies.Nautilus Biotechnology is currently under evaluation in short ratio category among related companies.
Nautilus Biotechnology ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Nautilus Biotechnology's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Nautilus Biotechnology's managers, analysts, and investors.Environmental | Governance | Social |
Nautilus Biotechnology Institutional Holders
Institutional Holdings refers to the ownership stake in Nautilus Biotechnology that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Nautilus Biotechnology's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Nautilus Biotechnology's value.| Shares | Clarius Group, Llc | 2024-03-31 | 619.9 K | Northern Trust Corp | 2023-12-31 | 533.8 K | Dimensional Fund Advisors, Inc. | 2024-03-31 | 479.9 K | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 440.8 K | Sentinel Trust Co Lba | 2023-12-31 | 300 K | Clearline Capital Lp | 2023-12-31 | 234.7 K | Hillman Co | 2024-03-31 | 200 K | Nuveen Asset Management, Llc | 2023-12-31 | 193.6 K | Bank Of New York Mellon Corp | 2023-12-31 | 150.3 K | Perceptive Advisors Llc | 2024-03-31 | 12.6 M | Cercano Management Llc | 2023-12-31 | 7.2 M |
Nautilus Fundamentals
| Return On Equity | -0.24 | ||||
| Return On Asset | -0.16 | ||||
| Current Valuation | 175.44 M | ||||
| Shares Outstanding | 125.27 M | ||||
| Shares Owned By Insiders | 33.60 % | ||||
| Shares Owned By Institutions | 50.04 % | ||||
| Number Of Shares Shorted | 1.1 M | ||||
| Price To Book | 1.16 X | ||||
| EBITDA | (70.45 M) | ||||
| Net Income | (63.67 M) | ||||
| Cash And Equivalents | 299.34 M | ||||
| Cash Per Share | 2.40 X | ||||
| Total Debt | 34.63 M | ||||
| Debt To Equity | 0.09 % | ||||
| Current Ratio | 49.75 X | ||||
| Book Value Per Share | 1.99 X | ||||
| Cash Flow From Operations | (51.71 M) | ||||
| Short Ratio | 16.65 X | ||||
| Earnings Per Share | (0.52) X | ||||
| Target Price | 4.25 | ||||
| Number Of Employees | 163 | ||||
| Beta | 1.03 | ||||
| Market Capitalization | 323.18 M | ||||
| Total Asset | 305.56 M | ||||
| Retained Earnings | (202.24 M) | ||||
| Working Capital | 167.72 M | ||||
| Net Asset | 305.56 M |
About Nautilus Biotechnology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Nautilus Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Nautilus Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Nautilus Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Nautilus Biotechnology
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Nautilus Biotechnology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Nautilus Biotechnology will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Nautilus Biotechnology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Nautilus Biotechnology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Nautilus Biotechnology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Nautilus Biotechnology to buy it.
The correlation of Nautilus Biotechnology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Nautilus Biotechnology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Nautilus Biotechnology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Nautilus Biotechnology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Nautilus Biotechnology Piotroski F Score and Nautilus Biotechnology Altman Z Score analysis. For more information on how to buy Nautilus Stock please use our How to Invest in Nautilus Biotechnology guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Complementary Tools for Nautilus Stock analysis
When running Nautilus Biotechnology's price analysis, check to measure Nautilus Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nautilus Biotechnology is operating at the current time. Most of Nautilus Biotechnology's value examination focuses on studying past and present price action to predict the probability of Nautilus Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nautilus Biotechnology's price. Additionally, you may evaluate how the addition of Nautilus Biotechnology to your portfolios can decrease your overall portfolio volatility.
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |
Is Nautilus Biotechnology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nautilus Biotechnology. If investors know Nautilus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nautilus Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.52) | Return On Assets (0.16) | Return On Equity (0.24) |
The market value of Nautilus Biotechnology is measured differently than its book value, which is the value of Nautilus that is recorded on the company's balance sheet. Investors also form their own opinion of Nautilus Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Nautilus Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nautilus Biotechnology's market value can be influenced by many factors that don't directly affect Nautilus Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nautilus Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Nautilus Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nautilus Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.